Metvix

Methyl aminolevulinate, the active ingredient in Metvix, is a photosensitizer presented as a topical formulation for topical use. It is employed in the treatment of actinic keratosis, a precancerous skin condition, by selective photodynamic therapy.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metvix is a topical photodynamic therapy agent used for precancerous skin lesions within the actinic keratosis disease family.

Actinic keratosis: treatment of sun‑exposed precancerous skin lesions, reducing the risk of progression to squamous cell carcinoma.

Metvix may cause a range of local and systemic reactions following application and light activation.

Common Side Effects: - Pain at the treatment site - Redness (erythema) - Swelling (edema) - Crusting or scaling - Itching or burning sensation - Temporary discoloration of the skin

Serious or Rare Side Effects: - Severe phototoxic reactions - Secondary infection of the treated area - Persistent scarring or ulceration - Intense or prolonged pain requiring medical attention - Allergic reactions such as urticaria or angioedema

Prior to using Metvix, several safety measures should be observed. - Sun exposure: Avoid direct sunlight on treated areas for at least 48 hours after therapy. - Protective dressings: Use occlusive dressings as instructed to limit unintended light exposure. - Skin integrity: Do not apply on broken, inflamed, or infected skin. - Pain monitoring: Assess and manage severe pain promptly; consider analgesics as prescribed. - Storage: Store at room temperature: keep in the original container, protect from light and moisture.

Metvix can interact with other agents that affect photosensitivity or skin healing.

Major Interactions (Avoid): - Systemic photosensitizing drugs: may increase phototoxic risk. - Tetracycline antibiotics: can enhance light sensitivity. - Porphyrinogenic agents: may exacerbate photodynamic effects.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may reduce therapeutic efficacy. - Antioxidant supplements: could interfere with reactive oxygen species generation. - Retinoids: may alter skin healing and response to therapy.